Resource Summary Report

Generated by RRID on Jul 29, 2026

Biotin anti-human CD19

RRID:AB_314233
Type: Antibody

Proper Citation

BioLegend Cat# 302203, RRID:AB_314233

Antibody Information

URL: http://antibodyregistry.org/AB_314233

Proper Citation: BioLegend Cat# 302203, RRID:AB_314233

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Biotin anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_314233

Vendor: BioLegend

Catalog Number: 302203

Alternative Catalog Numbers: 302204

Record Creation Time: 20250820T022839+0000

Record Last Update: 20250820T134137+0000

Ratings and Alerts

No rating or validation information has been found for Biotin anti-human CD19.

No alerts have been found for Biotin anti-human CD19.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Naef P, et al. (2025) IL-33/ST2 signaling in ILC2s drives exhaustion and myeloid skewing of HSCs in response to hematopoietic stress and aging. iScience, 28(5), 112378.

Rubino V, et al. (2024) IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T??cell therapy. Cell reports. Medicine, 5(11), 101826.

Gargaro M, et al. (2022) Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity, 55(6), 1032.

Riether C, et al. (2021) Metoclopramide treatment blocks CD93-signaling-mediated self-renewal of chronic myeloid leukemia stem cells. Cell reports, 34(4), 108663.